List of Excipients in Branded Drug TADALFIL

« Back to Dashboard

Generic Drugs Containing TADALFIL

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	tadalafil	0378-6971	ANHYDROUS LACTOSE
Mylan Pharmaceuticals Inc	tadalafil	0378-6971	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	tadalafil	0378-6971	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in TADALFIL?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM

Tadalafil Excipient Strategy and Commercial Opportunities

Last updated: October 7, 2026

Tadalafil is a low-solubility PDE5 inhibitor with established generic competition in erectile dysfunction and pulmonary arterial hypertension. The main commercial opportunity is not basic tablet replication. It is differentiated delivery: faster onset, improved swallowability, lower-dose exposure, combination products, pediatric-friendly formats, and products that improve adherence or reduce food-effect concerns.

The strongest excipient strategy combines particle-size control with robust oral solid-dose manufacturing. A conventional immediate-release tablet remains the lowest-risk route, while orally disintegrating, chewable, liquid, lipid-based, and amorphous-solid-dispersion products offer higher commercial differentiation but carry greater regulatory and intellectual-property risk.

What is tadalafil and where is it commercially used?

Tadalafil is a selective phosphodiesterase type 5 inhibitor marketed originally as Cialis by Eli Lilly for erectile dysfunction and benign prostatic hyperplasia. It is also marketed as Adcirca for pulmonary arterial hypertension. Generic tadalafil products are widely approved in the United States and other major markets.

Product or use	Typical strength	Regulatory use	Commercial position
Cialis, as-needed erectile dysfunction	10 mg, 20 mg	Erectile dysfunction	Originator product; generic competition
Cialis, once-daily erectile dysfunction	2.5 mg, 5 mg	Erectile dysfunction	Adherence-oriented dosing
Cialis, benign prostatic hyperplasia	5 mg	BPH, including ED/BPH	Generic and branded competition
Adcirca	20 mg tablets, administered as 40 mg daily	Pulmonary arterial hypertension	Specialist and reimbursement-driven market
Generic tadalafil	2.5 mg, 5 mg, 10 mg, 20 mg	Product-specific ANDAs	Price-led competition

The FDA approved Cialis in 2003 and Adcirca in 2009. Tadalafil’s long duration of action, commonly described as up to 36 hours for the approved erectile-dysfunction regimen, differentiates it from shorter-acting PDE5 inhibitors such as sildenafil and vardenafil. The prescribing label states that tadalafil exposure is not materially affected by food, although formulation design can still influence disintegration, dissolution, absorption rate, and patient experience (U.S. Food and Drug Administration [FDA], 2024a).

What excipients are used in tadalafil tablets?

The reference Cialis tablet uses a conventional immediate-release excipient system. Listed inactive ingredients include lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, sodium lauryl sulfate, magnesium stearate, hypromellose, triacetin, titanium dioxide, talc, and ferric oxide-based colorants (FDA, 2024a).

The formulation logic is straightforward:

Formulation function	Representative excipient	Strategic role
Dilution and tablet mass	Lactose monohydrate	Supports low-dose tablet manufacture
Disintegration	Croscarmellose sodium	Promotes rapid tablet breakup
Binder	Hydroxypropyl cellulose	Supports granule and tablet strength
Wetting	Sodium lauryl sulfate	Improves contact between hydrophobic drug particles and water
Lubrication	Magnesium stearate	Controls ejection force and tooling
Film coating	Hypromellose, triacetin, talc	Protects tablet and controls appearance
Color	Titanium dioxide, iron oxides	Product identification and branding

Tadalafil has low aqueous solubility and is generally treated as a dissolution-limited compound. The excipient program therefore needs to manage wetting, particle dispersion, granule porosity, tablet hardness, and dissolution consistency. Excessive hydrophobic lubrication can slow dissolution. Excessive surfactant can increase degradation or create process variability.

How should a generic tadalafil excipient strategy be designed?

The lowest-risk strategy is a bioequivalent immediate-release tablet using widely accepted excipients and a manufacturing process that avoids unnecessary formulation novelty.

Option 1: Conventional wet-granulated tablet

Wet granulation is suitable when the formulation requires improved content uniformity, flow, and tabletability. It can combine tadalafil with a hydrophilic binder and a superdisintegrant while adding the surfactant either intragranularly or extragranularly.

A typical development approach would evaluate:

• lactose or microcrystalline cellulose as the principal diluent;
• hydroxypropyl cellulose or povidone as binder;
• croscarmellose sodium or sodium starch glycolate as disintegrant;
• sodium lauryl sulfate or poloxamer as wetting agent;
• magnesium stearate or sodium stearyl fumarate as lubricant.

The key risk is preserving rapid dissolution after scale-up. Granulation endpoint, drying temperature, residual moisture, lubricant blending time, and compression force can materially change tadalafil release.

Option 2: Direct-compression tablet

Direct compression can reduce capital requirements and shorten the manufacturing process. It is attractive for high-volume generic supply if tadalafil particle engineering provides adequate flow and content uniformity.

Useful excipients include:

• spray-dried lactose;
• silicified microcrystalline cellulose;
• mannitol;
• crospovidone;
• low-substituted hydroxypropyl cellulose;
• sodium stearyl fumarate.

Direct compression is most competitive when the drug substance has controlled particle-size distribution and good bulk density. It also reduces water exposure, which can support chemical stability and simplified process validation.

Option 3: Micronized tadalafil

Micronization can increase surface area and improve dissolution without introducing a complex excipient system. It is often the most commercially defensible enhancement because it improves performance while preserving an immediate-release product profile.

The main controls are:

• particle-size distribution;
• agglomeration;
• electrostatic charging;
• content uniformity at low strengths;
• inhalation and operator exposure during manufacture;
• dissolution after compression and coating.

A particle-engineered tadalafil product can support a differentiated generic dossier, but the particle-size specification itself may become an important manufacturing trade secret or process patent target.

Option 4: Amorphous solid dispersion

An amorphous solid dispersion using polymers such as copovidone, hydroxypropyl methylcellulose acetate succinate, or Soluplus may improve apparent solubility. This route is technically more complex than a conventional tablet and may be unnecessary for a drug whose marketed reference product already has a successful immediate-release profile.

The commercial case is stronger for:

• lower-dose products;
• rapid-onset products;
• liquid or pediatric formulations;
• products requiring higher drug loading;
• markets where a new drug application or hybrid regulatory pathway can support formulation differentiation.

The critical risks are recrystallization, moisture sensitivity, polymer compatibility, and long-term dissolution drift.

What formulations are protected by tadalafil patents?

Tadalafil’s early patent estate covered the active compound, pharmaceutical compositions, polymorphic forms, and therapeutic uses. The most relevant commercial protection historically included:

Patent family area	Representative U.S. patent	Commercial relevance
Tadalafil compound and early pharmaceutical use	U.S. Patent No. 5,859,006	Foundational compound protection
Polymorphic or solid-state protection	U.S. Patent No. 6,821,975	Potential control over solid form and manufacturing
Dosing and therapeutic use	U.S. Patent No. 7,368,462	Relevance to once-daily or disease-specific use claims
Listed product patents	Current Orange Book entries	Determines ANDA Paragraph IV and certification exposure

Patent numbers and expiration dates should be assessed against the current FDA Orange Book, including pediatric extensions, terminal disclaimers, patent-use codes, and any later-listed patents. The foundational tadalafil exclusivity period has expired, and generic tadalafil is commercially established. The remaining strategic value is concentrated in formulation, delivery, manufacturing, and jurisdiction-specific rights rather than the basic tadalafil molecule.

When did tadalafil lose exclusivity and when can generics launch?

The original tadalafil compound patent protection expired in the United States in the late 2010s. Generic tadalafil products entered the U.S. market after approval of ANDAs and resolution of relevant Orange Book patent certifications.

A simplified U.S. exclusivity timeline is:

Event	Timing
Cialis FDA approval	November 2003
Adcirca FDA approval	May 2009
Foundational compound protection	Expired in the late 2010s
Generic Cialis-type tadalafil approvals	Began in the late 2010s
Current market	Multiple generic suppliers across strengths and indications

The practical launch date for an ANDA depends on the applicant’s Paragraph III or Paragraph IV certification, patent litigation, settlement terms, 180-day generic exclusivity, and any applicable pediatric extension. A company can obtain FDA approval before commercial launch if a patent settlement or delayed-entry provision restricts market entry.

What is the Orange Book status of tadalafil?

The Orange Book is central to tadalafil launch planning because Cialis and Adcirca listings may contain different patents, dosage forms, strengths, and use codes. A generic applicant must evaluate each reference-listed drug separately.

Key regulatory questions include:

1. Which reference product is being cited?
2. Does the proposed label include every patented indication?
3. Is the applicant filing a Paragraph III certification for delayed launch?
4. Is a Paragraph IV certification required for a listed patent?
5. Does the product require a section viii statement carving out a patented method of use?
6. Does the proposed formulation create a new patent risk outside the Orange Book?

A section viii carve-out can be commercially important for tadalafil products intended for erectile dysfunction or BPH when a patent covers a separate pulmonary arterial hypertension use. The label must exclude the patented method without undermining the approved indication.

Which companies are challenging tadalafil patents?

Tadalafil generic competition has involved major generic manufacturers and specialty pharmaceutical companies, including Teva, Mylan, Dr. Reddy’s Laboratories, Aurobindo, Torrent, Zydus, Sun Pharma, and other ANDA applicants. The precise challenger set varies by reference product, strength, indication, and market.

Paragraph IV litigation risk is concentrated in three areas:

• polymorphic or solid-form claims;
• dosing regimens and method-of-use claims;
• formulation or manufacturing claims that may be listed or asserted outside the Orange Book.

Tadalafil litigation is commercially less significant today than it was before generic entry because core molecule protection has expired. The more relevant litigation scenarios involve new delivery formats, reformulations, combination products, and allegations of infringement based on manufacturing processes.

What commercial opportunities exist for tadalafil excipient innovation?

Fast-disintegrating and orally disintegrating tablets

An orally disintegrating tablet can address swallowing difficulty and support discreet administration. Mannitol, crospovidone, croscarmellose sodium, and taste-masking agents are potential excipient tools.

The principal development barriers are tadalafil’s bitterness, tablet friability, dose loading, moisture sensitivity, and the need to demonstrate bioequivalence or justify a different regulatory pathway. An ODT is more commercially attractive in direct-to-consumer markets than in price-sensitive institutional channels.

Chewable tadalafil

A chewable tablet can support telehealth and consumer-oriented erectile-dysfunction brands. Taste masking is the decisive issue. Ion-exchange resins, polymer coatings, lipid barriers, sweeteners, flavors, and pH modifiers can be screened.

The product must avoid creating an impression of unapproved over-the-counter use. Tadalafil remains prescription-only in the United States, and advertising must remain consistent with the approved label.

Oral liquid and suspension

A liquid can serve patients with dysphagia and support specialty or international markets. Suspending agents such as xanthan gum, microcrystalline cellulose-carboxymethylcellulose, hypromellose, or poloxamers may be evaluated.

The main risks are dose uniformity, sedimentation, redispersibility, preservative effectiveness, chemical stability, and container compatibility. A liquid tadalafil product may have a stronger pediatric or institutional rationale than a mass-market erectile-dysfunction rationale.

Lipid-based formulations

Self-emulsifying drug-delivery systems can improve wetting and apparent solubilization. Candidate excipients include medium-chain triglycerides, mono- and diglycerides, polysorbates, polyethylene glycol esters, and other pharmaceutically accepted surfactants.

This approach may support softgels or oral solutions, but it introduces excipient tolerability, capsule compatibility, oxidation, scale-up, and food-effect questions. It is most suitable where rapid onset or reduced dose is commercially meaningful.

Combination products

Tadalafil combinations with finasteride or other BPH therapies may offer adherence benefits, but they create a more complex regulatory and intellectual-property profile. Combination products require dose-selection evidence, interaction assessment, manufacturing segregation, and new stability data.

A tadalafil-finasteride product has a clearer disease-management rationale than a tadalafil-sildenafil combination, which would raise cardiovascular, labeling, and clinical-development concerns.

How does tadalafil compare with sildenafil from an excipient and commercial perspective?

Attribute	Tadalafil	Sildenafil
Duration of action	Longer	Shorter
Solubility challenge	Significant	Significant
Primary dosage form	Immediate-release tablet	Immediate-release tablet
Differentiation opportunity	Once-daily, ODT, chewable, BPH combinations	Fast onset, dispersible, alternative administration
Generic competition	Mature	Mature
Key commercial advantage	Flexible timing and BPH positioning	Broad familiarity and lower-cost supply
Excipient priority	Wetting, particle engineering, rapid disintegration	Wetting, dissolution, taste and dispersibility

Tadalafil’s longer duration makes adherence and convenience stronger commercial themes. Sildenafil’s lower-cost generic position creates greater price pressure. A tadalafil product needs a clear delivery or patient-experience advantage to command a premium.

What generic launch risks exist for tadalafil?

The main risks are:

• failure to match dissolution across pH conditions;
• low-strength content-uniformity failures;
• excessive magnesium stearate exposure;
• polymorphic conversion during milling or storage;
• food-effect differences in novel formulations;
• patent claims covering a new solid form or dosage regimen;
• manufacturing-process infringement;
• inability to carve out patented indications;
• product liability linked to cardiovascular contraindications or drug interactions;
• online-channel diversion and counterfeit supply.

Manufacturing barriers are manageable for conventional tablets but increase sharply for amorphous dispersions, lipid systems, and taste-masked products. The strongest generic strategy is usually a robust immediate-release tablet supported by particle engineering, followed by a differentiated product only where market access and pricing justify development cost.

How strong is the current tadalafil patent estate?

The core estate is weak against ordinary generic tablets because compound protection has expired and multiple generic products are marketed. The residual estate can still be meaningful for:

• novel polymorphs;
• controlled particle-size specifications;
• amorphous dispersions;
• ODT and chewable formats;
• liquid suspensions;
• combination products;
• manufacturing processes;
• new methods of treating BPH or pulmonary hypertension.

Patent strength depends less on the number of claims than on whether the claims are difficult to design around and easy to detect in commercial products. A formulation claim covering a specific polymer ratio or dissolution profile may be commercially useful but vulnerable to alternative excipients. A process claim may be difficult to enforce without access to manufacturing evidence.

What licensing opportunities exist for tadalafil products?

Tadalafil originated from ICOS, which partnered with Eli Lilly for development and commercialization. Eli Lilly later acquired ICOS, consolidating Cialis rights within Lilly’s portfolio (Eli Lilly and Company, 2006).

Current licensing opportunities are more likely to involve:

• regional commercialization of generic tadalafil;
• contract development of ODT, chewable, or liquid formulations;
• access to micronized or engineered tadalafil drug substance;
• combination-product rights;
• manufacturing technology licenses;
• private-label telehealth distribution;
• specialty-market rights for PAH formulations.

A license is most defensible when it transfers a difficult-to-replicate formulation, regulatory dossier, manufacturing process, or market-access asset. A license covering ordinary tadalafil tablets has limited strategic value unless it includes low-cost supply, geographic exclusivity, or a differentiated brand.

Key Takeaways

• Tadalafil is a mature generic molecule with commercial value concentrated in delivery, adherence, and channel strategy.
• A conventional immediate-release tablet using lactose or microcrystalline cellulose, a superdisintegrant, binder, wetting agent, and lubricant is the lowest-risk formulation.
• Micronization and particle engineering offer the best balance between performance improvement and regulatory simplicity.
• ODT, chewable, liquid, lipid-based, and amorphous-dispersion products provide higher differentiation but increase development and patent risk.
• Core tadalafil patent protection has expired in the United States; current exposure is driven by product-specific Orange Book listings, use codes, formulation claims, and manufacturing patents.
• Section viii labeling strategies can be important where patented indications differ from the target generic indication.
• Tadalafil has stronger adherence and convenience positioning than sildenafil, while sildenafil generally creates greater price competition.
• The most attractive licensing assets are differentiated formulations, manufacturing technology, specialty-market rights, and combination products.

FAQs About Tadalafil Excipient and Commercial Strategy

Can tadalafil be formulated as an orally disintegrating tablet?

Yes. Mannitol, crospovidone, croscarmellose sodium, taste-masking polymers, and flavor systems can support an ODT. The principal challenges are bitterness, dose uniformity, moisture control, friability, and bioequivalence.

Which excipient most directly improves tadalafil dissolution?

A surfactant such as sodium lauryl sulfate or poloxamer can improve wetting, but dissolution also depends on particle size, granule porosity, compression force, and lubricant level. No single excipient reliably controls performance across all formulations.

Is tadalafil suitable for a pediatric formulation?

A liquid or dispersible formulation could address swallowing limitations, but the commercial opportunity depends on an approved pediatric indication and supporting clinical and regulatory data. Pediatric development would require more than simple reformulation.

Can a tadalafil formulation obtain new patent protection after molecule expiry?

Yes. New patents may cover a solid form, particle-size distribution, excipient combination, dosage form, dissolution profile, manufacturing process, or combination therapy. The claims must provide a genuine technical distinction and satisfy patentability requirements.

What is the best commercial entry strategy for a new tadalafil manufacturer?

For a generic manufacturer, the preferred sequence is a conventional immediate-release tablet, supported by reliable drug-substance sourcing and dissolution control. A differentiated ODT, chewable, liquid, or combination product should follow only where the target market can support premium pricing or stronger channel access.

References

Eli Lilly and Company. (2006). Eli Lilly and Company completes acquisition of ICOS Corporation. https://investor.lilly.com

U.S. Food and Drug Administration. (2024a). Cialis (tadalafil) prescribing information. https://www.accessdata.fda.gov

U.S. Food and Drug Administration. (2024b). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Food and Drug Administration. (2024c). Adcirca (tadalafil) prescribing information. https://www.accessdata.fda.gov

United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov

U.S. Patent No. 5,859,006. (1999). Pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione derivatives. United States Patent and Trademark Office.

U.S. Patent No. 6,821,975. (2004). Polymorphic forms of tadalafil. United States Patent and Trademark Office.

U.S. Patent No. 7,368,462. (2008). Use of tadalafil for the treatment of benign prostatic hyperplasia. United States Patent and Trademark Office.